Hanmi Science’s M&A on ‘JVM’ through investing KRW 129 billion
On the 9th, the holding company of Hanmi Pharm, Hanmi Science(CEO Jong-yoon Lim) officially announced the M&A of JVM, a global company in the automated medication management system field, through the stock swapping method.
Hanmi Science secured JVM’s 1,899,272 shares(30%) by investing the total ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
